Edison Inv. Res Weighs in on SIGA Technologies, Inc.’s FY2024 Earnings (NASDAQ:SIGA)

SIGA Technologies, Inc. (NASDAQ:SIGA – Get Rating) – Stock analysts at Edison Inv. Res issued their FY2024 EPS estimates for shares of SIGA Technologies in a research note issued to investors on Tuesday, March 14th. Edison Inv. Res analyst S. Romanoff forecasts that the company will post earnings of $1.12 per share for the year. The consensus estimate for SIGA Technologies’ current full-year earnings is $1.06 per share.

SIGA Technologies Price Performance

Shares of SIGA opened at $5.62 on Thursday. SIGA Technologies has a 52-week low of $5.11 and a 52-week high of $26.99. The firm’s fifty day moving average is $6.94 and its two-hundred day moving average is $8.75. The stock has a market cap of $405.76 million, a PE ratio of 12.22 and a beta of 0.87.

Institutional Investors Weigh In On SIGA Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in SIGA. Point72 Middle East FZE acquired a new stake in SIGA Technologies during the 4th quarter worth $27,000. Gladius Capital Management LP purchased a new position in shares of SIGA Technologies during the 4th quarter worth $32,000. Wipfli Financial Advisors LLC purchased a new position in shares of SIGA Technologies during the 3rd quarter worth $50,000. UBS Group AG raised its holdings in shares of SIGA Technologies by 30.3% during the 2nd quarter. UBS Group AG now owns 4,596 shares of the company’s stock worth $53,000 after acquiring an additional 1,070 shares during the period. Finally, State of Wyoming raised its holdings in shares of SIGA Technologies by 104.6% during the 4th quarter. State of Wyoming now owns 12,219 shares of the company’s stock worth $90,000 after acquiring an additional 6,247 shares during the period. Institutional investors and hedge funds own 39.44% of the company’s stock.

About SIGA Technologies

(Get Rating)

SIGA Technologies, Inc is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses.